Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study.
Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C. Wheatley-Price P, et al. Among authors: navani v. Lung Cancer. 2025 Jun;204:108583. doi: 10.1016/j.lungcan.2025.108583. Epub 2025 May 14. Lung Cancer. 2025. PMID: 40393235 Free article.
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.
Nassar AH, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman RS, Johnson DB, Grynberg S, Shapira R, Kwan JM, Woodford R, Long GV, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang EH, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Bou Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Juarez Herrera M, Foderaro S, Nana FA, Kim C, Sackstein P, Parikh K, Desai AP, Smith C, Cortellini A, Pinato DJ, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Ocejo Gallegos JA, Trent J, Nusrat S, Malvar C, McKay RR, Neilan TG, Choueiri TK, Naqash AR. Nassar AH, et al. Among authors: navani v. J Immunother Cancer. 2025 Mar 3;13(3):e009364. doi: 10.1136/jitc-2024-009364. J Immunother Cancer. 2025. PMID: 40032601 Free PMC article.
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis.
Gupta M, Wells C, Regan MM, Xie W, Navani V, Saliby RM, Basappa NS, Donskov F, Yuasa T, Takemura K, Kollmannsberger CK, Crumbaker M, Lalani AA, Powles T, Ebrahimi H, McKay RR, Lee JL, Kanesvaran R, Choueiri TK, Heng DYC. Gupta M, et al. Among authors: navani v. Eur Urol Oncol. 2025 Feb;8(1):171-178. doi: 10.1016/j.euo.2024.12.011. Epub 2024 Dec 31. Eur Urol Oncol. 2025. PMID: 39743422
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations.
Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR. Patil T, et al. Among authors: navani v. Lung Cancer. 2025 Jan;199:108040. doi: 10.1016/j.lungcan.2024.108040. Epub 2024 Nov 25. Lung Cancer. 2025. PMID: 39615411 Free PMC article.
Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.
Barghout SH, Zhan LJ, Raptis S, Al-Agha F, Esfahanian N, Popovacki A, Kasymjanova G, Proulx-Rocray F, Chan SWS, Richardson M, Brown MC, Patel D, Dean ML, Navani V, Moore E, Carvery L, Yan E, Goldshtein D, Cleary-Gosine J, Gibson AJ, Hubley L, Balaratnam K, Ngo T, Gill A, Black M, Sacher A, Bradbury PA, Shepherd FA, Leighl N, Cheema P, Kuruvilla S, Agulnik J, Banerji S, Juergens R, Blais N, Cheung W, Wheatley-Price P, Liu G, Snow S. Barghout SH, et al. Among authors: navani v. Lung Cancer. 2024 Aug;194:107898. doi: 10.1016/j.lungcan.2024.107898. Epub 2024 Jul 25. Lung Cancer. 2024. PMID: 39074423
What Is Ailing Oncology Clinical Trials? Can We Fix Them?
Mittal A, Moore S, Navani V, Jiang DM, Stewart DJ, Liu G, Wheatley-Price P. Mittal A, et al. Among authors: navani v. Curr Oncol. 2024 Jun 28;31(7):3738-3751. doi: 10.3390/curroncol31070275. Curr Oncol. 2024. PMID: 39057147 Free PMC article. Review.
New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.
Stewart DJ, Bradford JP, Sehdev S, Ramsay T, Navani V, Rawson NSB, Jiang DM, Gotfrit J, Wheatley-Price P, Liu G, Kaplan A, Spadafora S, Goodman SG, Auer RAC, Batist G. Stewart DJ, et al. Among authors: navani v. Curr Oncol. 2024 Apr 28;31(5):2453-2480. doi: 10.3390/curroncol31050184. Curr Oncol. 2024. PMID: 38785465 Free PMC article.
39 results